decisionhealth Newsletters, Answer Books - 2009 Issue 4 (April)
Anti-Kickback Advisory Opinion Summaries / 2003 OIG Advisory Opinions / Opinion 03-03 - Drug Manufacturer May Not Reimburse Patient Copayments
Subscribe or sign in to view the full article.
Article Overview
This article reviews an HHS Office of Inspector General advisory opinion from 2003 concerning a pharmaceutical manufacturer’s proposed patient assistance program and whether it could subsidize beneficiary cost-sharing for products used by financially needy patients. It is relevant to compliance, health care fraud and abuse, pharmaceutical reimbursement practices, and organizations that handle patient assistance or charity support programs. The summary focuses on the OIG’s risk assessment, the general reasons the arrangement was rejected, and the broader compliance implications for manufacturers and pharmacies.
Why This Topic Matters
Advisory opinions like this help compliance teams, legal counsel, and revenue-cycle professionals understand how patient assistance programs may implicate federal fraud and abuse rules. It is especially relevant to entities designing charitable support, copayment assistance, or similar benefit programs.
Article Sections
-
Summary of the proposed arrangement
Overview of the company’s existing patient assistance program and the proposed modification involving patient support and insurer billing. The section frames the compliance issue addressed by the advisory opinion.
-
OIG’s concerns and reasons for rejection
Discussion of the fraud-and-abuse risk analysis and the general reasons the arrangement was not approved. The section addresses competitive and beneficiary-related concerns at a high level.
-
Permissible alternatives and related note
General discussion of other assistance approaches mentioned in the opinion and a note about pharmacy copayment waivers under certain circumstances. This section highlights the broader compliance context without detailing operational steps.
What You Will Learn
- The scope of an OIG advisory opinion involving a pharmaceutical manufacturer’s patient assistance program
- Why beneficiary cost-sharing support can raise fraud and abuse concerns
- How advisory opinions distinguish between manufacturer assistance and other general support arrangements
- What types of compliance considerations are relevant to pharmacy copayment waiver questions
Who Should Read This
- Compliance officers
- Health care attorneys
- Pharmaceutical manufacturers
- Pharmacies
- Revenue cycle professionals
- Patient assistance program administrators
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com